No Data
[Brokerage Focus] China Merchants maintains a "Strongly Recommended" rating for Guoshengtang (02273), indicating AI's role in optimizing the allocation of Medical resources.
Jinwu Financial News | China Merchants Research Reports indicate that Gushengtang (02273) has built an AI Medical ecosystem covering areas such as intelligent diagnosis, health management, and telemedicine through independent research and development and collaboration with top Technology companies, leveraging Big Data and usage scenario advantages. Additionally, the report suggests that AI assists in optimizing the allocation of medical resources and achieving efficient management. The company attempts to conduct in-depth mining and intelligent analysis of multi-dimensional information such as hospital operation data, patient visit data, and medical quality data, enhancing performance in daily office areas such as diagnosis and treatment links, quality control, compliance risks, Pharmaceutical research and development, and supply chain management, thereby contributing to efficiency.
Pharmaceutical stocks generally rose, with KCP Pharmaceutical (02171) increasing by 25.29%. Institutions expect that after the first quarter report, the pharmaceutical Sector is likely to see an overall performance reversal in the Industry.
Jinwu Financial News | Pharmaceutical stocks have generally risen, with Keji Pharmaceutical (02171) up 25.29%, INNOCARE (09969) up 14.58%, REMEGEN (09995) up 12.88%, Yiming Anke (01541) up 12.25%, Lepu Biopharma (02157) up 10.67%, YSB (09885) up 6.88%, and Gushengtang (02273) up 6.71%. The Hong Kong stock Pharmaceutical ETF has risen 3.59%, and the Hong Kong Stock Connect Yinhua CSI Innovative Drugs Industry ETF has risen 4.05%. Ping An Securities stated that on January 17, 2025, the National Healthcare Security Administration will hold a '
Hong Kong Stock Movement | Gu Sheng Tang (02273) rises over 5% AI empowers traditional Chinese medicine diagnosis and treatment Institutions are Bullish on the company's value reassessment.
Guishengtang (02273) rose over 5%, as of the time of writing, it increased by 5.57%, reaching 36 Hong Kong dollars, with a transaction value of 0.115 billion Hong Kong dollars.
Trending Industry Today: ALI HEALTH Leads Losses In AI Medical Concept Stocks
Ping An Health, Yidu Technology, and others have been selected for the Goldman Sachs China AI Medical Care Index Stocks basket.
Recently, Goldman Sachs released a report focusing on the investment prospects of AI in the Medical sector in China, believing that it contains huge investment opportunities. After a private enterprise forum, market confidence in Chinese AI companies has significantly improved. Meanwhile, with the release of DeepSeek, and the Outflow of funds from the capital-intensive "Seven Wonders" Sector towards the AI field, related companies' stock prices have continued to rise. From the development data perspective, the growth rate of AI in China is astonishing. From 2019 to 2023, the number of foundational models in China has rapidly increased, surpassing that of the European Union and United Kingdom. In the gradually maturing AI application.
[Brokerage Focus] Goldman Sachs: China's AI Medical potential is substantial, valuation at a four-year low.
Goldman Sachs recently released a report focusing on the investment prospects of AI in the Medical field in China, believing that it contains enormous investment opportunities. After the private enterprise seminar, market confidence in Chinese AI companies significantly improved. At the same time, with the release of DeepSeek and the outflow of funds from the capital-intensive "Seven Wonders" Sector towards the AI field, the stock prices of related companies have continued to rise. From a developmental perspective, the speed of AI development in China is astonishing. Between 2019 and 2023, the number of foundational models in China has grown rapidly, surpassing that of the EU and the United Kingdom.
Investors Give Zhejiang Crystal-Optech Co., Ltd (SZSE:002273) Shares A 27% Hiding
